Frank Leebeek

List of Publications by Year
in descending order

289 papers	10,714 citations	34100 52 h-index	43886 91 g-index
290 all docs	290 docs citations	290 times ranked	10031 citing authors

#	Article	IF	Citations
1	In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients. European Journal of Clinical Pharmacology, 2022, 78, 237-249.	1.9	2
2	Von Willebrand disease type 2M: Correlation between genotype and phenotype. Journal of Thrombosis and Haemostasis, 2022, 20, 316-327.	3.8	5
3	Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. Journal of Thrombosis and Haemostasis, 2022, 20, 877-887.	3.8	3
4	Patientâ€reported outcomes in autosomal inherited bleeding disorders: A systematic literature review. Haemophilia, 2022, 28, 197-214.	2.1	7
5	Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Advances, 2022, 6, 121-128.	5.2	7
6	Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A. HemaSphere, 2022, 6, e679.	2.7	7
7	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). TH Open, 2022, 06, e60-e69.	1.4	1
8	Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study. BMJ Open, 2022, 12, e049493.	1.9	2
9	Outcomes of longâ€term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. Haemophilia, 2022, 28, 373-387.	2.1	5
10	Joint status of patients with nonsevere hemophilia A. Journal of Thrombosis and Haemostasis, 2022, 20, 1126-1137.	3.8	17
11	COVID-19 vaccination in patients with immune thrombocytopenia. Blood Advances, 2022, 6, 1637-1644.	5.2	30
12	Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients. British Journal of Haematology, 2022, 197, 497-501.	2.5	3
13	Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. Haemophilia, 2022, 28, 278-285.	2.1	1
14	Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood, 2022, 140, 89-98.	1.4	12
15	Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study. Haemophilia, 2022, 28, 814-821.	2.1	1
16	The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265.	5.2	10
17	Deep compartment models: A deep learning approach for the reliable prediction of timeâ€series data in pharmacokinetic modeling. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 934-945.	2.5	8
18	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011.	3.8	6

#	Article	IF	Citations
19	Diagnostic evaluation of the first macroscopic haematuria episode in adult haemophilia patients. Haemophilia, 2022, 28, .	2.1	0
20	Application of <scp>SHAP</scp> values for inferring the optimal functional form of covariates in pharmacokinetic modeling. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1100-1110.	2.5	8
21	The association between desmopressin exposure, FVIII response and side effects. Haemophilia, 2021, 27, e506-e509.	2.1	0
22	Treatment of acquired hemophilia A, a balancing act: results from a 27â€year Dutch cohort study. American Journal of Hematology, 2021, 96, 51-59.	4.1	21
23	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. British Journal of Clinical Pharmacology, 2021, 87, 2602-2613.	2.4	6
24	Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001â€“2018. Journal of Thrombosis and Haemostasis, 2021, 19, 645-653.	3.8	48
25	Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. Clinical Pharmacokinetics, 2021, 60, 1-16.	3.5	3
26	Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding. Journal of Thrombosis and Haemostasis, 2021, 19, 719-731.	3.8	5
27	A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. Blood Advances, 2021, 5, 113-121.	5.2	39
28	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	5.2	152
29	Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. HemaSphere, 2021, 5, e542.	2.7	5
30	Common and Rare Variants Genetic Association Analysis of Circulating Neutrophil Extracellular Traps. Frontiers in Immunology, 2021, 12, 615527.	4.8	8
31	In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. European Journal of Clinical Pharmacology, 2021, 77, 1193-1200.	1.9	3
32	Sports participation is not associated with adherence to prophylaxis in Dutch patients with haemophilia. Haemophilia, 2021, 27, e402-e405.	2.1	3
33	Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders. EClinicalMedicine, 2021, 32, 100726.	7.1	30
34	Population pharmacokinetics of the von Willebrand factorâ€“factor VIII interaction in patients with von Willebrand disease. Blood Advances, 2021, 5, 1513-1522.	5.2	5
35	Outcome of Surgical Interventions and Deliveries in Patients with Bleeding of Unknown Cause: An Observational Study. Thrombosis and Haemostasis, 2021, 121, 1409-1416.	3.4	7
36	Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. British Journal of Clinical Pharmacology, 2021, 87, 4408-4420.	2.4	4

#	Article	IF	Citations
37	Adherence to prophylaxis and its association with activation of selfâ€management and treatment satisfaction. Haemophilia, 2021, 27, 581-590.	2.1	8
38	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. Haemophilia, 2021, 27, 876-885.	2.1	14
39	New Developments in Diagnosis and Management of Acquired Hemophilia and Acquired von Willebrand Syndrome. HemaSphere, 2021, 5, e586.	2.7	10
40	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. Lancet Haematology,the, 2021, 8, e492-e502.	4.6	9
41	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
42	Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood, 2021, 138, 923-931.	1.4	67
43	Treatmentâ€related risk factors for inhibitor development in nonâ€severe hemophilia A after 50 cumulative exposure days: A caseâ€control study. Journal of Thrombosis and Haemostasis, 2021, 19, 2171-2181.	3.8	8
44	Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972â€“2019. Journal of Thrombosis and Haemostasis, 2021, 19, 2394-2406.	3.8	21
45	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	5.2	11
46	Validation of PROMIS Profileâ€29 in adults with hemophilia in the Netherlands. Journal of Thrombosis and Haemostasis, 2021, 19, 2687-2701.	3.8	16
47	Quantitative 3D microscopy highlights altered von Willebrand factor Î±â€granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12595.	2.3	7
48	Therapeutic plasma exchange for anticoagulant-refractory antiphospholipid syndrome with severe ischemic and necrotic skin lesions: A case series. Transfusion and Apheresis Science, 2021, 60, 103192.	1.0	2
49	Endothelial Dysfunction, Atherosclerosis, and Increase of von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine. Thrombosis and Haemostasis, 2021, 121, 676-686.	3.4	11
50	Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. Thrombosis and Haemostasis, 2021, 121, 731-740.	3.4	5
51	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	5.2	5
52	Efficacy and Safety of Recombinant Factor IX-FIAV and Bypassing Agents in Thrombin Generation Analyses in Hemophilia A Patient Plasma: The FIVITAS Study. Blood, 2021, 138, 3192-3192.	1.4	0
53	Hepatitis C virus in hemophilia: Healthâ€related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12616.	2.3	3
54	Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. Patient, 2020, 13, 201-210.	2.7	28

#	Article	IF	Citations
55	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate PÂ®/Humate PÂ® treatment in von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2020, 18, 295-305.	3.8	6
56	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
57	Effects of Diabetes Mellitus on Fibrin Clot Structure and Mechanics in a Model of Acute Neutrophil Extracellular Traps (NETs) Formation. International Journal of Molecular Sciences, 2020, 21, 7107.	4.1	14
58	Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. Thrombosis and Haemostasis, 2020, 120, 1407-1416.	3.4	3
59	The oneâ€stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in nonâ€severe haemophilia A: Superiority or nonâ€inferiority?. Haemophilia, 2020, 26, 916-922.	2.1	3
60	Acquired haemophilia A after alemtuzumab therapy. Haemophilia, 2020, 26, e337-e339.	2.1	7
61	How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease. Blood, 2020, 136, 2143-2150.	1.4	22
62	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 747-757.	3.4	8
63	Ex vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small-Interfering RNA. Thrombosis and Haemostasis, 2020, 120, 1569-1579.	3.4	11
64	ADAMTSâ€13 and bleeding phenotype in von Willebrand disease. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1331-1339.	2.3	3
65	COVIDâ€19â€associated immune thrombocytopenia. British Journal of Haematology, 2020, 190, e61-e64.	2.5	138
66	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERSâ€IPS, an international and collaborative crossâ€sectional study. Journal of Thrombosis and Haemostasis, 2020, 18, 2145-2154.	3.8	20
67	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 1056-1065.	3.4	5
68	Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization. PLoS ONE, 2020, 15, e0235048.	2.5	15
69	Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: A prospective cohort study. Haemophilia, 2020, 26, e106-e115.	2.1	15
70	Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial. British Journal of Haematology, 2020, 190, 916-922.	2.5	15
71	A Novel Quantitative Method for Analyzing Desmopressin in Human Plasma Using Liquid Chromatographyâ€“Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2020, 42, 880-885.	2.0	1
72	AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years. Blood, 2020, 136, 26-26.	1.4	13

#	Article	IF	Citations
73	Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial. Blood, 2020, 136, 13-13.	1.4	2
74	First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. Blood, 2020, 136, LBA-6-LBA-6.	1.4	11
75	Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. Blood, 2020, 136, 15-16.	1.4	0
76	Low Von Willebrand Factor: Cut-Off Value for Diagnosis and Risk Score to Predict Bleeding Incidence. Blood, 2020, 136, 18-19.	1.4	0
77	Title is missing!. , 2020, 15, e0235048.		0
78	Title is missing!. , 2020, 15, e0235048.		0
79	Title is missing!. , 2020, 15, e0235048.		0
80	Title is missing!. , 2020, 15, e0235048.		0
81	Title is missing!. , 2020, 15, e0235048.		0
82	Title is missing!. , 2020, 15, e0235048.		0
83	Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target. Haemophilia, 2019, 25, 960-968.	2.1	4
84	Severe postpartum haemorrhage as first presenting symptom of an inherited bleeding disorder. Haemophilia, 2019, 25, 1051-1058.	2.1	7
85	How I manage severe von Willebrand disease. British Journal of Haematology, 2019, 187, 418-430.	2.5	24
86	Decoration of Fibrin with Extracellular Chaperones. Thrombosis and Haemostasis, 2019, 119, 1624-1631.	3.4	5
87	A prothrombotic von Willebrand factor variant. Blood, 2019, 133, 288-289.	1.4	2
88	Thyroid Function and Cardiovascular Disease: The Mediating Role of Coagulation Factors. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3203-3212.	3.6	19
89	BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. American Journal of Hematology, 2019, 94, E201-E205.	4.1	15
90	The effect of hospital-based antithrombotic stewardship on adherence to anticoagulant guidelines. International Journal of Clinical Pharmacy, 2019, 41, 691-699.	2.1	11

#	Article	IF	Citations
91	Association between fibrinogen and fibrinogen Î³â€™ and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study. Thrombosis Research, 2019, 177, 130-135.	1.7	11
92	Porto-sinusoidal vascular disease: proposal and description of a novel entity. The Lancet Gastroenterology and Hepatology, 2019, 4, 399-411.	8.1	149
93	Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. Journal of Hepatology, 2019, 71, 175-199.	3.7	80
94	P1675Evolution of lactate dehydrogenase levels in patients with HeartMate II, HeartWare and HeartMate 3 left ventricular assist devices during first-year follow-up. European Heart Journal, 2019, 40, .	2.2	0
95	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances, 2019, 3, 3241-3247.	5.2	85
96	von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. Blood Advances, 2019, 3, 4147-4154.	5.2	12
97	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	2.7	43
98	Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. Therapeutic Drug Monitoring, 2019, 41, 192-212.	2.0	10
99	Anticoagulant medication errors in hospitals and primary care: a cross-sectional study. International Journal for Quality in Health Care, 2019, 31, 346-352.	1.8	19
100	Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. Journal of Thrombosis and Haemostasis, 2019, 17, 319-328.	3.8	25
101	The prevalence and burden of hand and wrist bleeds in von Willebrand disease. Haemophilia, 2019, 25, e35-e38.	2.1	6
102	Sports participation and physical activity in patients with von Willebrand disease. Haemophilia, 2019, 25, 101-108.	2.1	14
103	Analytical variation in factor VIII oneâ€stage and chromogenic assays: Experiences from the ECAT external quality assessment programme. Haemophilia, 2019, 25, 162-169.	2.1	20
104	Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B. Blood, 2019, 134, 2059-2059.	1.4	42
105	One Year Data from a Phase 2b Trial of AMT-061 (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B. Blood, 2019, 134, 3348-3348.	1.4	4
106	Bleeding in critical care associated with left ventricular assist devices: pathophysiology, symptoms, and management. Hematology American Society of Hematology Education Program, 2019, 2019, 88-96.	2.5	19
107	VWF and FVIII Levels after Desmopressin Are Associated with the Bleeding Phenotype in Type 1 VWD. Blood, 2019, 134, 1116-1116.	1.4	0
108	Clingen Coagulation Factor Deficiency Variant Curation Expert Panel: Meeting the Need for Recommendations to Curate Variants in the Coagulation Factor Genes. Blood, 2019, 134, 5794-5794.	1.4	1

#	Article	IF	Citations
109	Super-Resolution Immunofluorescence Imaging of Platelet Granules. Blood, 2019, 134, 3613-3613.	1.4	1
110	Incidence, predictors and clinical outcome of early bleeding events in patients undergoing a left ventricular assist device implant. European Journal of Cardio-thoracic Surgery, 2018, 54, 176-182.	1.4	20
111	Analysis of current perioperative management with Haemate^{Â®} P/Humate P^{Â®} in von Willebrand disease: Identifying the need for personalized treatment. Haemophilia, 2018, 24, 460-470.	2.1	28
112	The level of circulating fibroblast activation protein correlates with incorporation of alpha-2-antiplasmin into the fibrin clot. Thrombosis Research, 2018, 166, 19-21.	1.7	11
113	Risk of Venous Thrombosis in Antithrombin Deficiency: A Systematic Review and Bayesian Meta-analysis. Seminars in Thrombosis and Hemostasis, 2018, 44, 315-326.	2.7	48
114	Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. European Heart Journal, 2018, 39, 1740-1747.	2.2	51
115	Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. Blood Reviews, 2018, 32, 265-271.	5.7	41
116	Acquired coagulopathy in patients with left ventricular assist devices. Journal of Thrombosis and Haemostasis, 2018, 16, 429-440.	3.8	51
117	Perioperative replacement therapy in haemophilia B: An appeal to â€œBâ€•more precise. Haemophilia, 2018, 24, 611-618.	2.1	7
118	Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII. Thrombosis and Haemostasis, 2018, 118, 514-525.	3.4	19
119	Gene therapy with adeno-associated virus vector 5â€“human factor IX in adults with hemophilia B. Blood, 2018, 131, 1022-1031.	1.4	236
120	5992Improved haemocompatibility in the heartmate 3 left ventricular assist device assessed through lactate dehydrogenase levels over time. European Heart Journal, 2018, 39, .	2.2	0
121	Hemophilia B in a female with intellectual disability caused by a deletion of Xq26.3q28 encompassing the F9. Molecular Genetics & Genomic Medicine, 2018, 6, 1220-1224.	1.2	5
122	Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. Thrombosis and Haemostasis, 2018, 118, 1690-1700.	3.4	10
123	Clinically relevant differences between assays for von Willebrand factor activity. Journal of Thrombosis and Haemostasis, 2018, 16, 2413-2424.	3.8	26
124	Positioning extended halfâ€life concentrates for future use: a practical proposal. Haemophilia, 2018, 24, e369-e372.	2.1	4
125	Comorbidities associated with higher von Willebrand factor (<scp>VWF</scp>) levels may explain the ageâ€related increase of <scp>VWF</scp> in von Willebrand disease. British Journal of Haematology, 2018, 182, 93-105.	2.5	39
126	Emerging Concepts in Immune Thrombocytopenia. Frontiers in Immunology, 2018, 9, 880.	4.8	155

#	Article	IF	Citations
127	Women prefer proactive support from providers for treatment of heavy menstrual bleeding: A qualitative study in adult women with moderate or severe Von Willebrand disease. Haemophilia, 2018, 24, 950-956.	2.1	8
128	Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. Thrombosis and Haemostasis, 2018, 47, 621-629.	3.4	8
129	Von Willebrand disease: Clinical conundrums. Haemophilia, 2018, 24, 37-43.	2.1	9
130	Reduction in Annualized Bleeding and Factor IX Consumption up to 2.5 Years in Adults with Severe or Moderate-Severe Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy. Blood, 2018, 132, 3476-3476.	1.4	3
131	Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.. Blood, 2018, 132, 1184-1184.	1.4	0
132	Prospective Observation on the Use of Von Willebrand Factor (VWF) Concentrates in a Large Cohort of Type 3 Von Willebrand Disease (VWD): Interim (18-months) Analyses on 149 Cases Enrolled into the 3Winters-Ips Project. Blood, 2018, 132, 2464-2464.	1.4	0
133	Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project). Blood, 2018, 132, 2465-2465.	1.4	2
134	Monitoring of treatment with vitamin K antagonists: recombinant thromboplastins are more sensitive to factor VII than tissue-extract thromboplastins. Journal of Thrombosis and Haemostasis, 2017, 15, 500-506.	3.8	5
135	Von Willebrandâ€™s Disease. New England Journal of Medicine, 2017, 376, 701-702.	27.0	35
136	Intensity of factor VIII treatment and the development of inhibitors in nonâ€severe hemophilia A patients: results of the INSIGHT caseâ€“control study. Journal of Thrombosis and Haemostasis, 2017, 15, 1422-1429.	3.8	28
137	Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen. Haemophilia, 2017, 23, 861-867.	2.1	5
138	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica, 2017, 102, 1486-1493.	3.5	24
139	Mortality caused by intracranial bleeding in nonâ€severe hemophilia A patients. Journal of Thrombosis and Haemostasis, 2017, 15, 1115-1122.	3.8	19
140	Plasma levels of plasminogen activator inhibitorâ€1 and bleeding phenotype in patients with von Willebrand disease. Haemophilia, 2017, 23, 437-443.	2.1	6
141	Monitoring storage induced changes in the platelet proteome employing label free quantitative mass spectrometry. Scientific Reports, 2017, 7, 11045.	3.3	27
142	In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients. Journal of Thrombosis and Haemostasis, 2017, 15, 1737-1746.	3.8	12
143	Current and Emerging Options for the Management of Inherited von Willebrand Disease. Drugs, 2017, 77, 1531-1547.	10.9	28
144	Low VWF: an established mild bleeding disorder?. Blood, 2017, 130, 2241-2242.	1.4	5

#	Article	IF	Citations
145	ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus: a population-based cohort study. Diabetologia, 2017, 60, 280-286.	6.3	23
146	Pitfalls in the diagnosis of hemophilia severity: What to do?. Pediatric Blood and Cancer, 2017, 64, e26276.	1.5	2
147	Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII: reply. Journal of Thrombosis and Haemostasis, 2017, 15, 205-206.	3.8	1
148	Antithrombotic treatment with directâ€acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	3.9	178
149	Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. PLoS ONE, 2017, 12, e0178987.	2.5	16
150	Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications. Clinical Chemistry, 2016, 62, 1639-1646.	3.2	37
151	Evaluation of the role of the <scp>GPI</scp>bâ€<scp>IX</scp>â€V receptor complex in development of the platelet storage lesion. Vox Sanguinis, 2016, 111, 247-256.	1.5	33
152	A diagnostic approach to mild bleeding disorders. Journal of Thrombosis and Haemostasis, 2016, 14, 1507-1516.	3.8	63
153	Side effects of desmopressin in patients with bleeding disorders. Haemophilia, 2016, 22, 39-45.	2.1	46
154	Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications. Journal of Thrombosis and Haemostasis, 2016, 14, 468-478.	3.8	39
155	P1â€013: Von Willebrand Factor and the Risk of Dementia: A Populationâ€Based Study. Alzheimer's and Dementia, 2016, 12, P404.	0.8	1
156	Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy outcomes during and after hospitalisation: a study protocol. BMJ Open, 2016, 6, e011537.	1.9	7
157	OC-10 - Disseminated intravascular coagulation at diagnosis strongly predicts both arterial and venous thrombosis in acute myeloid leukemia patients. Thrombosis Research, 2016, 140, S172.	1.7	15
158	Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology, 2016, 63, 138-147.	7.3	253
159	Update of thrombosis in multiple myeloma. Thrombosis Research, 2016, 140, S76-S80.	1.7	40
160	von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study. American Journal of Kidney Diseases, 2016, 68, 726-732.	1.9	12
161	Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII. Journal of Thrombosis and Haemostasis, 2016, 14, 1453-1461.	3.8	45
162	Low ADAMTSâ€13 activity and the risk of coronary heart disease â€“ a prospective cohort study: the Rotterdam Study. Journal of Thrombosis and Haemostasis, 2016, 14, 2114-2120.	3.8	37

#	Article	IF	Citations
163	Von Willebrandâ€™s Disease. New England Journal of Medicine, 2016, 375, 2067-2080.	27.0	389
164	Natural heterogeneity of Î±2-antiplasmin: functional and clinical consequences. Blood, 2016, 127, 538-545.	1.4	68
165	A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica, 2016, 101, 1159-1169.	3.5	39
166	Von Willebrand Factor, ADAMTS13, and the Risk of Mortality. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2446-2451.	2.4	56
167	Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility. Expert Review of Hematology, 2016, 9, 1023-1030.	2.2	15
168	Joint surgery in von Willebrand disease: a multicentre crossâ€sectional study. Haemophilia, 2016, 22, 256-262.	2.1	6
169	Impact of point-of-care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study. Journal of Thrombosis and Haemostasis, 2016, 14, 695-703.	3.8	8
170	Genome-wide association studies identify genetic loci for low von Willebrand factor levels. European Journal of Human Genetics, 2016, 24, 1035-1040.	2.8	45
171	Interim Results from a Dose Escalating Study of AMT-060 (AAV5-hFIX) Gene Transfer in Adult Patients with Severe Hemophilia B. Blood, 2016, 128, 2314-2314.	1.4	5
172	No Association Between Normalization of VWF Levels and Bleeding Phenotype in Patients with Type 1 VWD - from the Win Study. Blood, 2016, 128, 2577-2577.	1.4	3
173	Label Free Quantitative Mass Spectrometry Identifies Processes Linked to Platelet Degranulation As Early Events during Platelet Storage. Blood, 2016, 128, 2638-2638.	1.4	1
174	Clinical Joint Outcome after Joint Bleeds in Patients with Von Willebrand Disease Is Comparable to Moderate and Severe Hemophilia A Despite Fewer Joint Bleeds. Blood, 2016, 128, 3789-3789.	1.4	1
175	Elevated Levels of Circulating Nucleosomes Are Not Associated with Venous Thrombosis or Neutrophil Activation in Patients with Multiple Myeloma. Blood, 2016, 128, 274-274.	1.4	2
176	CLEC4M and STXBP5 gene variations contribute to vonÂWillebrand factor level variation in von Willebrand disease. Journal of Thrombosis and Haemostasis, 2015, 13, 956-966.	3.8	45
177	Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. Journal of Thrombosis and Haemostasis, 2015, 13, 1585-1589.	3.8	44
178	von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood, 2015, 125, 3006-3013.	1.4	62
179	Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood, 2015, 126, 2038-2046.	1.4	126
180	Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood, 2015, 126, 2739-2746.	1.4	125

#	Article	IF	Citations
181	Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Thrombosis and Haemostasis, 2015, 113, 577-584.	3.4	35
182	Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia, 2015, 21, 505-512.	2.1	77
183	Plasma ADAMTSâ€13 levels and the risk of myocardial infarction: an individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2015, 13, 1396-1404.	3.8	52
184	Bleeding spectrum in children with moderate or severe von <scp>W</scp>illebrand disease: <scp>R</scp>elevance of pediatricâ€specific bleeding. American Journal of Hematology, 2015, 90, 1142-1148.	4.1	46
185	Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy. Blood Coagulation and Fibrinolysis, 2015, 26, 383-388.	1.0	46
186	The â€œOPTI-CLOTâ€•trial. Thrombosis and Haemostasis, 2015, 114, 639-644.	3.4	22
187	Infusion of <scp>DDAVP</scp> does not improve primary hemostasis in patients with cirrhosis. Liver International, 2015, 35, 1809-1815.	3.9	32
188	Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population. Journal of Hepatology, 2015, 63, 1459-1465.	3.7	31
189	Plasma levels of soluble fibroblast activation protein in arterial thrombosis; determinants and cleavage of its substrate alpha-2-antiplasmin. International Journal of Cardiology, 2015, 178, 105-110.	1.7	27
190	Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. Haematologica, 2015, 100, e226-e228.	3.5	39
191	Genetic variants in the ADAMTS13 and SUPT3H genes are associated with ADAMTS13 activity. Blood, 2015, 125, 3949-3955.	1.4	24
192	The Fibrinolytic Status in Liver Diseases. Seminars in Thrombosis and Hemostasis, 2015, 41, 474-480.	2.7	66
193	Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a crossâ€sectional study. Haemophilia, 2015, 21, e185-92.	2.1	43
194	A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. European Journal of Clinical Pharmacology, 2015, 71, 921-929.	1.9	58
195	Interferon gamma receptor 2 gene variants are associated with liver fibrosis in the general population: the Rotterdam Study. Gut, 2015, 64, 692-694.	12.1	3
196	Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies. Blood, 2015, 126, 3510-3510.	1.4	2
197	Performance Related Factors Are the Main Determinants of the von Willebrand Factor Response to Exhaustive Physical Exercise. PLoS ONE, 2014, 9, e91687.	2.5	22
198	von Willebrand disease and aging: an evolving phenotype. Journal of Thrombosis and Haemostasis, 2014, 12, 1066-1075.	3.8	87

#	Article	IF	Citations
199	Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the <scp>VERITAS</scp>â€Pro scale. Haemophilia, 2014, 20, 616-623.	2.1	32
200	Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Reviews, 2014, 28, 167-178.	5.7	115
201	Low ADAMTS13 Activity Is a Strong Risk Factor for Ischemic Stroke: A Prospective Cohort Study - the Rotterdam Study. Blood, 2014, 124, 113-113.	1.4	1
202	Infusion of DDAVP Does Not Improve Primary Hemostasis in Patients with Cirrhosis. Blood, 2014, 124, 5044-5044.	1.4	1
203	Phase 1-2 Clinical Trial of a Recombinant AAV5 Vector Containing the Human FIX Gene in Patients with Severe or Moderately Severe Haemophilia B. Blood, 2014, 124, 5948-5948.	1.4	3
204	Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: â€œTackling a Moving Targetâ€•(â€œOPTI-CLOTâ€•Studies). Blood, 2014, 124, 5031-5031.	1.4	0
205	Towards Successful Implementation of Pharmacokinetic-Guided Prophylactic Dosing of Clotting Factor Concentrate in Hemophilia; The Doâ€™s and Donâ€™ts after Discrete Choice Experiment Analysis. Blood, 2014, 124, 5038-5038.	1.4	0
206	Quality of haemophilia care in The Netherlands: new standards for optimal care. Blood Transfusion, 2014, 12 Suppl 3, s501-4.	0.4	8
207	Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia, 2013, 19, 76-81.	2.1	99
208	Bleeding Phenotype in Children with Moderate or Severe Von Willebrand Disease â€“ Iatrogenic bleeding is the presenting symptom in 42% of the index cases. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 101-101.	0.0	0
209	Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. Journal of Thrombosis and Haemostasis, 2013, 11, 452-459.	3.8	89
210	Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis, 2013, 230, 210-215.	0.8	34
211	Increased Nâ€terminal cleavage of alphaâ€2â€antiplasmin in patients with liver cirrhosis. Journal of Thrombosis and Haemostasis, 2013, 11, 2029-2036.	3.8	38
212	Reduced prevalence of arterial thrombosis in von Willebrand disease. Journal of Thrombosis and Haemostasis, 2013, 11, 845-854.	3.8	79
213	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122, 1954-1962.	1.4	188
214	Response to desmopressin is strongly dependent on F8 gene mutation type in mild and moderate haemophilia A. Thrombosis and Haemostasis, 2013, 109, 440-449.	3.4	25
215	Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood, 2012, 120, 4921-4928.	1.4	303
216	Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification. Annals of Internal Medicine, 2012, 156, 438.	3.9	330

#	Article	IF	Citations
217	Risk and management of thrombosis in multiple myeloma. Thrombosis Research, 2012, 129, S88-S92.	1.7	21
218	Prognostic markers in young patients with premature coronary heart disease. Atherosclerosis, 2012, 224, 213-217.	0.8	27
219	Diagnosis and management of haemophilia. BMJ, The, 2012, 344, e2707-e2707.	6.0	82
220	Hemophilic arthropathy in patients with von Willebrand disease. Blood Reviews, 2012, 26, 261-266.	5.7	31
221	Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thrombosis and Haemostasis, 2012, 108, 683-692.	3.4	87
222	Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease. Haemophilia, 2012, 18, 444-451.	2.1	10
223	Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study. Journal of Thrombosis and Haemostasis, 2012, 10, 550-556.	3.8	14
224	von Willebrand factor plasma levels, genetic variations and coronary heart disease in an older population. Journal of Thrombosis and Haemostasis, 2012, 10, 1262-1269.	3.8	48
225	Inhibitor incidence after intensive <scp>FVIII</scp> replacement for surgery in mild and moderate haemophilia <scp>A</scp>: a prospective national study in the <scp>N</scp>etherlands. British Journal of Haematology, 2012, 157, 747-752.	2.5	23
226	Effect of Genetic Variation in STXBP5 and STX2 on von Willebrand Factor and Bleeding Phenotype in Type 1 von Willebrand Disease Patients. PLoS ONE, 2012, 7, e40624.	2.5	30
227	Prothrombotic disorders in abdominal vein thrombosis. Netherlands Journal of Medicine, 2012, 70, 400-5.	0.5	22
228	Hypercoagulability and Hypofibrinolysis and Risk of Deep Vein Thrombosis and Splanchnic Vein Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 485-493.	2.4	54
229	Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thrombosis and Haemostasis, 2011, 106, 885-892.	3.4	64
230	High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thrombosis Research, 2011, 127, 254-258.	1.7	16
231	The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thrombosis and Haemostasis, 2011, 106, 165-171.	3.4	19
232	Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood, 2011, 117, 1393-1399.	1.4	55
233	Impact of von Willebrand disease on healthâ€related quality of life in a pediatric population. Journal of Thrombosis and Haemostasis, 2011, 9, 502-509.	3.8	30
234	Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. Journal of Thrombosis and Haemostasis, 2011, 9, 899-908.	3.8	80

#	Article	IF	Citations
235	Relationship between thrombospondin gene variations, von Willebrand factor levels and the risk of coronary heart disease in an older population. Journal of Thrombosis and Haemostasis, 2011, 9, 1415-1417.	3.8	7
236	Longâ€term followâ€up of patients with portal vein thrombosis and myeloproliferative neoplasms. Journal of Thrombosis and Haemostasis, 2011, 9, 2208-2214.	3.8	68
237	Diagnosis and Management of von Willebrand Disease in The Netherlands. Seminars in Thrombosis and Hemostasis, 2011, 37, 480-487.	2.7	25
238	Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood, 2010, 115, 388-395.	1.4	43
239	High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. Blood, 2010, 116, 22-26.	1.4	74
240	Treatment of multiple myeloma and arterial thrombosis. Annals of Hematology, 2010, 89, 419-420.	1.8	5
241	von Willebrand factor propeptide and the occurrence of a first ischemic stroke. Journal of Thrombosis and Haemostasis, 2010, 8, 1424-1426.	3.8	22
242	Healthâ€related quality of life among adult patients with moderate and severe von Willebrand disease. Journal of Thrombosis and Haemostasis, 2010, 8, 1492-1499.	3.8	75
243	A Review of Hereditary and Acquired Coagulation Disorders in the Aetiology of Ischaemic Stroke. International Journal of Stroke, 2010, 5, 385-394.	5.9	18
244	Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thrombosis and Haemostasis, 2010, 103, 1181-1187.	3.4	40
245	Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor VII, Factor VIII, and von Willebrand Factor. Circulation, 2010, 121, 1382-1392.	1.6	311
246	Effect of Genetic Variations in Syntaxin-Binding Protein-5 and Syntaxin-2 on von Willebrand Factor Concentration and Cardiovascular Risk. Circulation: Cardiovascular Genetics, 2010, 3, 507-512.	5.1	40
247	High von Willebrand Factor Levels Increase the Risk of Stroke. Stroke, 2010, 41, 2151-2156.	2.0	135
248	Active von Willebrand factor and the risk of stroke. Atherosclerosis, 2010, 208, 322-323.	0.8	5
249	JAK2 Germline Genetic Variation In Budd-Chiari Syndrome and Portal Vein Thrombosis. Blood, 2010, 116, 4212-4212.	1.4	4
250	Fibrinogen Î³' In the Budd-Chiari Syndrome: Results From a Multicenter Case-Control Study. Blood, 2010, 116, 4213-4213.	1.4	0
251	Effects of Ambient Air Pollution on Hemostasis and Inflammation. Environmental Health Perspectives, 2009, 117, 995-1001.	6.0	90
252	Hypofibrinolysis is a risk factor for arterial thrombosis at young age. British Journal of Haematology, 2009, 145, 115-120.	2.5	74

#	Article	IF	Citations
253	The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. Journal of Thrombosis and Haemostasis, 2009, 7, 919-927.	3.8	63
254	Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis, 2009, 207, 250-254.	0.8	110
255	Superimposed Coagulopathic Conditions in Cirrhosis: Infection and Endogenous Heparinoids, Renal Failure, and Endothelial Dysfunction. Clinics in Liver Disease, 2009, 13, 33-42.	2.1	19
256	Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leukemia Research, 2008, 32, 1078-1084.	0.8	65
257	Incidence of diagnosis of subsegmental pulmonary emboli using multidetector row and single-detector row computed tomography. Journal of Thrombosis and Haemostasis, 2008, 6, 384-386.	3.8	11
258	Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. Journal of Thrombosis and Haemostasis, 2008, 6, 268-276.	3.8	38
259	Absence of the JAK2 V617F mutation in patients with arterial thrombosis without overt myeloproliferative disease. Journal of Thrombosis and Haemostasis, 2008, 6, 1606-1607.	3.8	6
260	Frequency of the von Willebrand factor Tyr1584Cys polymorphism in arterial thrombosis. British Journal of Haematology, 2008, 140, 578-579.	2.5	5
261	Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke. British Journal of Haematology, 2008, 143, 734-737.	2.5	4
262	Transient focal cerebral ischaemia and bilateral pulmonary embolism after desmopressin treatment for von Willebrandâ€™s disease. Haemophilia, 2008, 14, 1133-1134.	2.1	8
263	Fibrinogen Î³â€² in Ischemic Stroke. Stroke, 2008, 39, 1033-1035.	2.0	62
264	Microparticle-Associated Tissue Factor Activity and Venous Thrombosis in Multiple Myeloma.. Blood, 2008, 112, 1812-1812.	1.4	0
265	Willebrand in the Netherlands: WiN Study. Background and Study Design. Blood, 2008, 112, 4510-4510.	1.4	0
266	Circulating Endothelial Cells: A Potential Parameter of Organ Damage in Sickle Cell Anemia?. Blood, 2008, 112, 4798-4798.	1.4	0
267	Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica, 2007, 92, 279-280.	3.5	84
268	Prothrombotic Coagulation Abnormalities in Patients with Paraprotein-Producing B-Cell Disorders. Clinical Lymphoma and Myeloma, 2007, 7, 462-466.	1.4	34
269	High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke. Stroke, 2006, 37, 2672-2677.	2.0	219
270	Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch. Transfusion, 2006, 46, 1705-1711.	1.6	51

#	Article	IF	Citations
271	Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology, 2006, 44, 53-61.	7.3	534
272	O-Linked Glycosylation with Sialylated T-Antigen: A Novel Carbohydrate Determinant of von Willebrand Factor Antigen Levels.. Blood, 2006, 108, 178-178.	1.4	4
273	Evidence for an Enhanced Fibrinolytic Capacity in Liver Cirrhosis Measured with a New Global Fibrinolysis Test in Whole Blood.. Blood, 2006, 108, 1627-1627.	1.4	26
274	Myeloproliferative Disease in the Pathogenesis and Survival of Budd-Chiari Syndrome.. Blood, 2006, 108, 1480-1480.	1.4	1
275	Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica, 2006, 91, 1712-3.	3.5	58
276	Temporary relief of symptomatic Von Willebrand disease by multiple myeloma. Journal of Thrombosis and Haemostasis, 2005, 3, 1088-1089.	3.8	4
277	High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. Journal of Thrombosis and Haemostasis, 2005, 3, 2211-2218.	3.8	86
278	Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thrombosis and Haemostasis, 2005, 94, 1341-1343.	3.4	37
279	The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. Thrombosis and Haemostasis, 2005, 93, 92-96.	3.4	30
280	Genetic Variability of von Willebrand Factor and Atherosclerosis. Circulation, 2004, 110, e57.	1.6	3
281	Effective and safe use of recombinant factor VIIa (NovoSevenR) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII. Haemophilia, 2004, 10, 250-253.	2.1	20
282	Relevance of Routine Bacterial Screening of Pooled Random Platelet Concentrates with the BactalertÂ® System.. Blood, 2004, 104, 3626-3626.	1.4	0
283	Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thrombosis and Haemostasis, 2003, 90, 92-100.	3.4	39
284	Haemostatic abnormalities in patients with liver disease. Journal of Hepatology, 2002, 37, 280-287.	3.7	212
285	Thrombin-Activatable Fibrinolysis Inhibitor Deficiency in Cirrhosis Is Not Associated With Increased Plasma Fibrinolysis. Gastroenterology, 2001, 121, 131-139.	1.3	264
286	A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood, 2001, 98, 1992-1993.	1.4	112
287	Acute Effect of Pegvisomant on Cardiovascular Risk Markers in Healthy Men: Implications for the Pathogenesis of Atherosclerosis in GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5165-5171.	3.6	18
288	A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology, 1991, 101, 1382-1390.	1.3	116

#	Article	IF	Citations
289	Mild Haemostatic Problems Associated with Congenital Heterozygous Î±2-Antiplasmin Deficiency. Thrombosis and Haemostasis, 1988, 59, 096-100.	3.4	28